REUTERS/Brendan McDermid
Billionaire investor Stanley Druckenmiller's Duquesne Family Office took up new stakes in Palantir, Citigroup, and Coupang during the first quarter of 2021, regulatory filings show.
Druckenmiller scooped up 5,983,992 shares of Palantir worth $139,367,000 at the time of the March 31 filing. It's the opposite move from Third Point's Dan Loeb, who sold all of his Palantir stake in the first quarter of 2021. The big data surveillance company is down nearly 9% year-to-date.
Like Loeb, Druckenmiller trimmed his stake in Amazon, selling 7,105 shares. His fund now holds 75,648 shares of Amazon for a value of $234,061,000 at the filing time.
Druckenmiller also added a big bet on newly public company Coupang. The Korean e-commerce company was the largest US IPO in the first quarter of 2021, raising $4.6 billion, according to Renaissance Capital. Druckenmiller added 714,285 shares.
The investor also appears to be betting on the financial sector. He took a new stake in Citigroup, purchasing 2,124,909 million shares worth $154,587,000 at the time of filing. He also scooped up 258,420 of JPMorgan Chase, and added positions in Visa and Mastercard.
Druckenmiller liquidated his positions in cyclical stocks like Disney, cruise liner Carnival Crop, and Live Nation Entertainment. However, he appears to be still betting on the rebound of travel out of the pandemic, as seen by his new $69.7 million stake in online travel company Booking Holdings Inc.
In a recent CNBC interview, the investor said that a "monkey could make money in this market," due to the Federal Reserve's easy monetary policies that have pumped ample liquidity into all financial markets.
NOW WATCH: Why 'moist' is one of the most hated words in the English language
See Also:
- 20 million adults could dive into the cryptocurrency market over the next year, nearly doubling today's retail investor base, says crypto exchange Gemini
- Morgan Stanley's Mike Wilson was right about the last two market sell-offs. He lays out 3 ways stock investors can position for a challenging reopening environment that could bring a 20% drop
- Novavax extends 2-day loss to 31% as the biotech firm delays seeking emergency authorization for its COVID-19 vaccine
